To: [Recipient’s email]

From: MPR

Subject lines:

[Discover Alvogen's Teriparatide Injection: a lower-cost treatment option]

[Alvogen's Teriparatide Injection may cost your patients as little as $0 per month]

[Savings program to support eligible Teriparatide Injection patients]

Preheader:

Alvogen's Teriparatide Injection: the first FDA-approved teriparatide alternative to Forteo*

Savings available from Alvogen

Discover a lower-cost^† option for your patients with Сommercial insurance coverage^‡

Indications

(See below for warning regarding potential risk of osteosarcoma.)

Teriparatide Injection is a prescription medicine used in both men and postmenopausal women with osteoporosis who are at high risk for having bone fractures—defined as those who have had a fracture related to osteoporosis, who are at high risk for fracture, or who cannot use other osteoporosis treatments. It is also used for treating osteoporosis associated with glucocorticoid medicines, such as prednisone, in patients who are at high risk for fracture.

Teriparatide Injection Savings Program

Help your eligible patients pay as little as $0 for each 28-day prescription of Alvogen's Teriparatide Injection^†

HELP YOUR PATIENTS SAVE $

Sample trial offer for Teriparatide Injection available from Alvogen to be sent directly to your office

Click on the link below to get started:

TO REQUEST SAMPLES, CONTACT ALVOGENREP@ALVOGEN.COM

Alvogen's Teriparatide Injection: alternative* to Forteo^® (teriparatide injection)

*Offers the SAME benefits as Forteo^®

	•		Active Ingredient teriparatide
	•		STRENGTH 20 mcg/day
	•		Dosing 28 days
	•		Indications 3 patient populations
	•		Administration single-patient-use multi-dose pen

Disclaimer: Alvogen's Teriparatide Injection is not a generic of and is not automatically substitutable for Forteo.

*Offers the SAME benefits as Forteo^®

	•		Active Ingredient teriparatide
	•		STRENGTH 20 mcg/day
	•		Dosing 28 days
	•		Indications 3 patient populations
	•		Administration

Disclaimer: Alvogen's Teriparatide Injection is not a generic of and is not automatically substitutable for Forteo.

^†	Lower WAC and AWP compared to Forteo^®.
^‡	Eligibility restrictions apply.

Terms and Conditions

Eligible patients can pay as little as $0 and receive up to $12,000 off the patient's co-pay or out of pocket expenses annually of Teriparatide Injection, Solution. Maximum monthly benefit applies. A valid Prescriber ID# is required on the prescription.

Patient Instructions: In order to redeem this offer you must have a valid prescription for Teriparatide Injection, Solution. Follow the dosage instructions given by the doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients with questions about Teriparatide Injection, Solution Savings offer should call 833.330.0806.

Pharmacist: When you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs for this prescription. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section below.

Restrictions: This offer is valid in the United States. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare or other federal or state health programs (such as medical assistance programs). Cash Discount Cards and other non-insurance plans are not valid as primary under this offer.

If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. Program managed by ConnectiveRx on behalf of Alvogen Pharmaceuticals. The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

Pharmacist instructions for a patient with an Eligible Third Party

Submit the claim to the primary Third Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code,
(e.g., 8). The patient is responsible for cost over WAC per month and the card pays up to $12,000 annually. Reimbursement will be received from CHANGE HEALTHCARE.

Valid Other Coverage Code required.

For any questions regarding Change Healthcare online processing, please call the Help Desk at 800.433.4893

Terms and Conditions

Eligible patients will pay a minimum of $0 and receive up to $12,000 off the patient's co-pay or out of pocket expenses annually of Teriparatide Injection, Solution. Maximum monthly benefit applies. A valid Prescriber ID# is required on the prescription.

Pharmacist instructions for a patient with an Eligible Third Party

Submit the claim to the primary Third Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code, (e.g., 8). The patient is responsible for cost over WAC per month and the card pays up to $12,000 annually. Reimbursement will be received from CHANGE HEALTHCARE.

Valid Other Coverage Code required.
For any questions regarding Change Healthcare online processing, please call the Help Desk at 800.433.4893

Important Safety Information

WARNING: POTENTIAL RISK OF OSTEOSARCOMA

In male and female rats, teriparatide injection caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide injection ranging from 3 to 60 times the exposure in humans given a 20-mcg dose. Because of the uncertain relevance of the rat osteosarcoma finding to humans, prescribe teriparatide injection only for patients for whom the potential benefits are considered to outweigh the potential risk. Teriparatide injection should not be prescribed for patients who are at increased baseline risk for osteosarcoma (including those with Paget’s disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).

Contraindications

Hypersensitivity to teriparatide injection or to any of its excipients. Reactions have included angioedema and anaphylaxis.

Warnings and Precautions

Teriparatide injection should not be prescribed for patients at increased baseline risk of osteosarcoma. These patients include: Paget’s disease of bone, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy.

The safety and efficacy of teriparatide injection has not been evaluated beyond two years of treatment, and use for more than two years during a patient’s lifetime is not recommended.

Patients with the following should not be treated with teriparatide injection: bone metastases or a history of skeletal malignancies, metabolic bone diseases other than osteoporosis, or hypercalcemic disorders.

Use with caution in patients with active or recent urolithiasis because of risk of exacerbation. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Teriparatide injection should be administered so that patients can sit or lie down if symptoms of orthostatic hypotension occur. In short-term clinical studies, transient orthostatic hypotension was observed in 5% of patients.

Patients receiving digoxin should use teriparatide injection with caution, as it may transiently increase serum calcium and hypercalcemia may predispose patients to digitalis toxicity.

Adverse Reactions

The most common adverse reactions in clinical trials include: arthralgia (10.1% vs. 8.4% placebo), pain (21.3% vs. 20.5% placebo), and nausea (8.5% vs. 6.7% placebo). Other adverse reactions include: dizziness, leg cramps, joint aches, and injection site reactions.

Pregnancy and Lactation

There is no available data on teriparatide injection use in pregnant women. Consider discontinuing when pregnancy is recognized.

It is not known whether teriparatide injection is excreted in human milk, affects human milk production, or has effects on the breastfed infant. Breastfeeding is not recommended.

For additional safety information, please see the Prescribing Information and full User Manual that accompanies the delivery device.

Forteo is a registered trademark of Eli Lilly and Company, which has no affiliation with Alvogen.

ALV-TERI-022 07/21

Subscribed as: {{contact.email}} | Privacy Policy | Terms & Conditions

You have received this email communication based upon your profession and specialty.
Click here to update/complete your profile or unsubscribe from these promotional mailings here.

© {{'now'|date:'%Y'}} Haymarket Media, Inc. | 275 7th Avenue, 10th Floor, New York, NY 10001